Cutting-Edge Medicines Context Therapeutics is advancing innovative medicines for solid tumors, with a focus on T cell engaging antibodies. Companies in the oncology space seeking novel treatments may be interested in exploring partnership opportunities with Context Therapeutics to expand their product offerings.
Experienced Leadership Team With key appointments to its Board of Directors and leadership team, including prominent figures in the industry, Context Therapeutics demonstrates a commitment to expertise and strategic guidance. Businesses looking to collaborate with established biopharmaceutical leaders could leverage these connections for potential collaborations or shared projects.
Recent Funding Boost Having secured $100M in funding through a private placement, Context Therapeutics has the financial backing to drive its research and development efforts forward. Investors or companies looking to support cutting-edge oncology research may find value in exploring investment or partnership opportunities with Context Therapeutics.
Tech-Savvy Solutions Context Therapeutics utilizes a modern tech stack, incorporating tools like Google Analytics, jQuery, and Webpack. Tech companies or service providers specializing in supporting biotech firms with digital solutions could present offerings that complement or enhance Context Therapeutics' technological infrastructure.
Strategic Partnerships By entering into exclusive worldwide license agreements and collaborations with companies like BioAtla, Context Therapeutics showcases a willingness to engage in strategic partnerships for the development and commercialization of innovative therapies. Biotech firms seeking expansion through partnerships could explore synergistic opportunities with Context Therapeutics.
Context Therapeutics uses 8 technology products and services including Google Analytics, Squarespace, Typekit, and more. Explore Context Therapeutics's tech stack below.
| Context Therapeutics Email Formats | Percentage |
| FLast@contexttherapeutics.com | 50% |
| FLast@contexttherapeutics.com | 50% |
Biotechnology ResearchPennsylvania, United States11-50 Employees
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.
Company Overview
Media & News
Funding & FinancialsContext Therapeutics has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $100M.
Funding & FinancialsContext Therapeutics has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $100M.
1-888-653-2347 
support@leadiq.com